Real-World RCC Data: ICI+TKI Improves PFS, Not Survival

This IPTW-adjusted multicenter cohort offers pharmacists comparative effectiveness data for choosing between dual checkpoint blockade and checkpoint inhibitor plus tyrosine kinase inhibitor combinations in first-line metastatic renal cell carcinoma.

📅 Journal publication: Sep 2026 · Last updated: Oct 7, 2026

nivolumabipilimumabpembrolizumabaxitinibavelumabcabozantiniblenvatinibimmune checkpoint inhibitorstyrosine kinase inhibitorsrenal cell carcinomametastatic RCCfirst-line therapyreal-world evidenceIPTWretrospective cohort Oncology Pharmacy

Background Information

TKI combos may improve initial disease control in metastatic RCC.

This study informs treatment selection for metastatic renal cell carcinoma (RCC) by comparing dual immune checkpoint blockade with combinations including tyrosine kinase inhibitors (TKIs), using real-world data. ICI plus TKI showed a trend toward longer progression-free survival (PFS) than ICI plus ICI (28.7 vs. 16.6 months, HR 0.69, p = 0.050), though overall survival (OS) was similar. Findings suggest TKI combinations may offer better initial disease control, but no long-term survival advantage was noted. Interpretation requires caution due to retrospective design and potential confounding. Consider individual patient priorities when choosing between ICI and TKI-containing regimens for metastatic RCC.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Ohba K, Oki M, Matsuda T, Miyata H, Kikuchi H, Inoue T, Shin T, Sekine Y, Narita S, Naito S, Tsuchiya N, Naito H, Sugimoto M, Numakura K, Kobayashi S, Ueda K, Igawa T, Mitsunari K, Matsuo T, Imamura R

Citation: Ohba K, Oki M, Matsuda T, et al. Real-World Comparison of Dual Checkpoint Blockade and Immunotherapy Plus TKIs in Metastatic RCC. Cancer medicine. 2026;15(9):e72265. doi:10.1002/cam4.72265

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →